EMPLICITI 300 mg/1 (Elotuzumab INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION) 300 mg/1

Elotuzumab is a lyophilized powder for solution used in intravenous therapy. This medication is often associated with certain blood disorders and is available in a 300 mg strength per vial.

Strength

300 mg/1

Pack Size

1 VIAL, SINGLE-USE in 1 CARTON (0003-2291-11) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1

Manufacturer / TM Owner

E.R. Squibb & Sons, L.L.C.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Elotuzumab is primarily used in the management of specific blood-related conditions. It is often combined with other treatments to support immune system function and target abnormal cells. Patients may wonder, 'What is elotuzumab used for?' and typically find it prescribed for conditions requiring immune modulation.

Side Effects

Common effects of elotuzumab may include infusion-related reactions such as fever, chills, and fatigue. Some individuals might experience respiratory symptoms or general discomfort during administration. These effects are generally monitored by healthcare providers during treatment.

Precautions & Warnings

Elotuzumab should be handled with care, ensuring proper reconstitution and administration by trained professionals. Patients with a history of severe allergic reactions or certain infections should discuss their medical history with their healthcare provider before starting treatment.

Avoid Interactions

Elotuzumab may interact with other medications, particularly those that affect the immune system. It is important to inform healthcare providers about all current medications, including over-the-counter drugs and supplements, to avoid potential interactions.

References

Frequently Asked Questions

Elotuzumab is used in the treatment of certain blood disorders, often in combination with other therapies.

Elotuzumab is administered intravenously after reconstitution of the lyophilized powder.

Common side effects may include infusion-related reactions such as fever, chills, and fatigue.

Elotuzumab may interact with other medications, so it is important to consult a healthcare provider before combining treatments.

Patients with a history of severe allergic reactions or certain infections should discuss their medical history with their healthcare provider before starting elotuzumab.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.